A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database
{{output}}
IntroductionAntibody-drug conjugates (ADCs) are cancer therapies that deliver cytotoxic agents to tumor cells. Despite their specificity, toxicity remains a concern. Cardiac adverse events (CAEs) have not been studied in prospective trials, and guidance remain... ...
